- Home
- AIRI vs SYBX Comparison
AIRI vs SYBX Comparison
Compare AIRI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- SYBX
- Stock Information
- Founded
- AIRI 1979
- SYBX N/A
- Country
- AIRI United States
- SYBX United States
- Employees
- AIRI N/A
- SYBX N/A
- Industry
- AIRI Military/Government/Technical
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- SYBX Health Care
- Exchange
- AIRI Nasdaq
- SYBX Nasdaq
- Market Cap
- AIRI 13.4M
- SYBX 13.6M
- IPO Year
- AIRI N/A
- SYBX N/A
- Fundamental
- Price
- AIRI $3.44
- SYBX $1.22
- Analyst Decision
- AIRI
- SYBX
- Analyst Count
- AIRI 0
- SYBX 0
- Target Price
- AIRI N/A
- SYBX N/A
- AVG Volume (30 Days)
- AIRI 24.9K
- SYBX 12.2K
- Earning Date
- AIRI 05-15-2025
- SYBX 06-10-2025
- Dividend Yield
- AIRI N/A
- SYBX N/A
- EPS Growth
- AIRI N/A
- SYBX N/A
- EPS
- AIRI N/A
- SYBX 0.21
- Revenue
- AIRI $53,182,000.00
- SYBX N/A
- Revenue This Year
- AIRI $5.59
- SYBX N/A
- Revenue Next Year
- AIRI $5.00
- SYBX N/A
- P/E Ratio
- AIRI N/A
- SYBX $5.87
- Revenue Growth
- AIRI 0.29
- SYBX N/A
- 52 Week Low
- AIRI $3.00
- SYBX $0.90
- 52 Week High
- AIRI $9.44
- SYBX $1.88
- Technical
- Relative Strength Index (RSI)
- AIRI 48.58
- SYBX 59.89
- Support Level
- AIRI $3.38
- SYBX $1.00
- Resistance Level
- AIRI $3.51
- SYBX $1.27
- Average True Range (ATR)
- AIRI 0.16
- SYBX 0.04
- MACD
- AIRI -0.00
- SYBX 0.01
- Stochastic Oscillator
- AIRI 68.75
- SYBX 74.49
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.